Study identifies predictors of treatment response to citalopram for agitation

Abstract

A multivariate analysis using outcome data from the Citalopram for Agitation in Alzheimer Disease (CitAD) study identified several variables that predicted effectiveness of the antidepressant in reducing symptoms of agitation. Patients most likely to have positive outcomes with citalopram included those with milder cognitive impairment and a moderate level of baseline agitation, while patients with moderate to severe cognitive impairment and more severe baseline agitation were less likely to see improvement with the antidepressant.